← Trials/Trial dossier/NCT02547818

COGNITE

CompletedPhase 3

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Lead sponsor

AZTherapies, Inc.

Assets

ALZT-OP1a / ALZT-OP1b

Listed sites

121

Recruiting sites

Enrollment

620

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Study partner/caregiver required•AD symptomatic therapy: stable ≥12 weeks

Primary endpoint

•Clinical Dementia Rating-Sum of Boxes (CDR-SB)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDAZT-001

NCT IDNCT02547818

Timeline

Milestones

Study first posted2015-09-11estimated

Study start2015-09-15actual

Primary completion2020-11-13actual

Study completion2020-11-18actual

Last update posted2021-11-10actual

Assets

Drug assets

ALZT-OP1a ALZT-OP1b

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

Maximum age79 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•55-79 years old;

•≥ 8 years of education;

•Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol;

•Evidence of early AD, as defined by all of the following:

1. Memory complaint by subject or study partner that is verified by a study partner;

2. Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):

-≤ 8 for 16 or more years of education, or

-≤ 4 for 8-15 years of education;

-Essentially preserved general cognitive function;

-Largely intact functional activities;

-Not demented;

•Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF Aβ-42 levels ≥ 180 pg/mL and ≤ 690 pg/mL;

•Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;

•Must be fluent in the language of the cognitive testing material being administered;

•Stability of permitted medications for 4 weeks prior to study start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study;

•Visual and auditory acuity adequate for neuropsychological testing;

•Good general health with no diseases expected to interfere with the study;

•Must provide written informed consent for APOe4 genotype testing;

•Must provide written informed consent for CSF sampling

Exclusion criteria

•Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;

•Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol;

•History of schizophrenia or bipolar disorder (DSM-IV criteria);

•History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria);

•Currently taking medications that could lead to difficulty complying with the protocol; subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry;

•Investigational agents are prohibited one month prior to entry and for the duration of the trial;

•Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);

•Currently taking cromolyn, or have taken cromolyn, within the past 12 months;

•Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or other chronic inflammatory diseases ("chronic" defined as 3200 mg/day for >2 weeks);

•Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses;

•Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.);

•Allergies to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin;

•Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs;

•Uncontrolled chronic asthma;

•Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < predicted value for subject AND FEV1 < 70% of predicted value, indicating moderate or severe respiratory obstruction;

•Taking inhaled protein products on a chronic basis;

•Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol;

•Pregnancy or lactation for female subjects of child-bearing potential (i.e., < two years post-menopausal or not surgically sterile);

•For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods;

•Severe renal or hepatic impairment.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Safety / tolerability / PK

Global cognition

1 endpoint

Primary/protocol endpoint

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

Time frame:Baseline and Week 72

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Number of Treatment Emergent Adverse Events (TEAE)

Time frame:72 weeks

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.